Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly To Cease Development Of Alzheimer's Drug: A Blow To The Amyloid Hypothesis?

Executive Summary

Eli Lilly said August 17 it would halt development of its Phase III Alzheimer's drug candidate semagacestat, casting some doubt on the efficacy of novel gamma secretase inhibitor drugs and slowing Lilly's late-stage pipeline as the company struggles to replace future revenues that will be lost to drugs going off patent

You may also be interested in...



Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another

Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.

Bristol Opens A Phase III Door Into Gamma Secretase As Lilly Closes Another

Whether Bristol-Myers Squibb Co. and others can succeed at bringing a gamma secretase inhibitor to market for the treatment of Alzheimer's disease is far from certain.

Roche Is Sudden Pioneer In Alzheimer's Research With New Trial In Early Patients

Using a biomarker and investigational diagnostic, Roche has initiated a Phase II clinical trial of an amyloid-beta peptide antibody, gantenerumab, in patients with only mild cognitive deficits.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel